AU2017285213B2 - Expression of NKG2D activating ligand proteins for sensitizing cancer cells to attack by cytotoxic immune cells - Google Patents

Expression of NKG2D activating ligand proteins for sensitizing cancer cells to attack by cytotoxic immune cells Download PDF

Info

Publication number
AU2017285213B2
AU2017285213B2 AU2017285213A AU2017285213A AU2017285213B2 AU 2017285213 B2 AU2017285213 B2 AU 2017285213B2 AU 2017285213 A AU2017285213 A AU 2017285213A AU 2017285213 A AU2017285213 A AU 2017285213A AU 2017285213 B2 AU2017285213 B2 AU 2017285213B2
Authority
AU
Australia
Prior art keywords
vector
ulbp3
cell
cells
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2017285213A
Other languages
English (en)
Other versions
AU2017285213A1 (en
Inventor
Ndukaku Mgbechinyere AMANKULOR
Joseph C. Glorioso III.
Paola Grandi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Pittsburgh
Original Assignee
University of Pittsburgh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Pittsburgh filed Critical University of Pittsburgh
Publication of AU2017285213A1 publication Critical patent/AU2017285213A1/en
Application granted granted Critical
Publication of AU2017285213B2 publication Critical patent/AU2017285213B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16632—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16641—Use of virus, viral particle or viral elements as a vector
    • C12N2710/16643—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AU2017285213A 2016-06-14 2017-06-14 Expression of NKG2D activating ligand proteins for sensitizing cancer cells to attack by cytotoxic immune cells Active AU2017285213B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662350095P 2016-06-14 2016-06-14
US62/350,095 2016-06-14
PCT/US2017/037531 WO2017218689A1 (en) 2016-06-14 2017-06-14 Expression of nkg2d activating ligand proteins for sensitizing cancer cells to attack by cytotoxic immune cells

Publications (2)

Publication Number Publication Date
AU2017285213A1 AU2017285213A1 (en) 2019-01-17
AU2017285213B2 true AU2017285213B2 (en) 2024-05-16

Family

ID=60664263

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2017285213A Active AU2017285213B2 (en) 2016-06-14 2017-06-14 Expression of NKG2D activating ligand proteins for sensitizing cancer cells to attack by cytotoxic immune cells

Country Status (9)

Country Link
US (1) US11427625B2 (enExample)
EP (1) EP3468588A4 (enExample)
JP (1) JP7184337B2 (enExample)
CN (1) CN109475613B (enExample)
AU (1) AU2017285213B2 (enExample)
CA (1) CA3027857C (enExample)
MX (1) MX2018015542A (enExample)
NZ (1) NZ749586A (enExample)
WO (1) WO2017218689A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20200042904A (ko) 2017-07-26 2020-04-24 온코루스, 인크. 종양용해성 바이러스 벡터 및 그의 용도
JP2020530454A (ja) 2017-08-07 2020-10-22 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 安全な細胞治療薬を生成するためのプラットフォーム
EP3833765A1 (en) * 2017-08-09 2021-06-16 The Ohio State Innovation Foundation Oncolytic virus carrying e-cadherin and uses thereof
MA52542A (fr) * 2018-04-13 2021-02-24 Bluebird Bio Inc Thérapie cellulaire adoptive
WO2020091958A1 (en) * 2018-11-01 2020-05-07 Onconetics Pharmaceuticals, Inc. Multi-component vector systems, methods of making, and uses thereof
TW202038947A (zh) 2018-11-28 2020-11-01 德商創新分子有限責任公司 在與溶瘤病毒之組合療法中治療癌症的解旋酶引子酶抑制劑
TWI852977B (zh) 2019-01-10 2024-08-21 美商健生生物科技公司 前列腺新抗原及其用途
EP4061405A1 (en) 2019-11-18 2022-09-28 Janssen Biotech, Inc. Vaccines based on mutant calr and jak2 and their uses
EP4175664A2 (en) 2020-07-06 2023-05-10 Janssen Biotech, Inc. Prostate neoantigens and their uses
CA3215085A1 (en) * 2021-04-08 2022-10-13 Immvira Biopharmaceuticals Co., Limited Genetically modified oncolytic herpes simplex virus delivering chemokine and tumor associated/specific antigen
CN118389408B (zh) * 2024-06-26 2024-11-29 淇嘉科技(苏州)有限公司 炎症性肠病及纤维化体外精准模拟方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU742757C (en) 1997-12-17 2007-05-17 Immunex Corporation Cell surface glycoproteins associated with human B cell lymphomas - ULBP, DNA and polypeptides
EP1451333B1 (en) 2001-10-04 2009-06-24 Immunex Corporation Ul16 binding protein 4
US20150165065A1 (en) 2009-12-31 2015-06-18 Avidbiotics Corp. Non-natural mic proteins
WO2012006181A2 (en) * 2010-06-29 2012-01-12 Mount Sinai School Of Medicine Compositions and methods for inhibiting oncogenic micrornas and treatment of cancer
US20130156808A1 (en) * 2011-11-22 2013-06-20 Stipan Jonjic Vaccine comprising beta-herpesvirus
JP6588024B2 (ja) * 2013-10-28 2019-10-09 ユニヴァーシティ オヴ ピッツバーグ オヴ ザ コモンウェルス システム オヴ ハイアー エデュケーション 腫瘍溶解性ｈｓｖベクター

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Deng, W et al., 2015. A shed NKG2D ligand that promotes natural killer cell activation and tumor rejection. Science, 348(6230), pages 136-139. *
Friese, M.A. et al., 2003. MICA/NKG2D-mediated immunogene therapy of experimental gliomas. Cancer research, 63(24), pages 8996-9006. *

Also Published As

Publication number Publication date
NZ749586A (en) 2023-06-30
JP2019517815A (ja) 2019-06-27
MX2018015542A (es) 2019-10-14
EP3468588A1 (en) 2019-04-17
CA3027857A1 (en) 2017-12-21
CA3027857C (en) 2023-07-25
AU2017285213A1 (en) 2019-01-17
WO2017218689A9 (en) 2018-12-13
CN109475613B (zh) 2024-02-20
JP7184337B2 (ja) 2022-12-06
WO2017218689A1 (en) 2017-12-21
US11427625B2 (en) 2022-08-30
EP3468588A4 (en) 2019-12-11
CN109475613A (zh) 2019-03-15
US20200148742A1 (en) 2020-05-14

Similar Documents

Publication Publication Date Title
AU2017285213B2 (en) Expression of NKG2D activating ligand proteins for sensitizing cancer cells to attack by cytotoxic immune cells
JP7262134B2 (ja) 腫瘍溶解性ｈｓｖベクター
AU2022204729A1 (en) Compositions and methods for the treatment of wounds, disorders, and diseases of the skin
Grandi et al. Design and application of oncolytic HSV vectors for glioblastoma therapy
JP2020505390A (ja) Ｃｒｉｓｐｒ治療薬を送達するためのウイルスベクターとしてのレンチウイルスおよび非組み込みレンチウイルス
Burton et al. Multi-modal combination gene therapy for malignant glioma using replication-defective HSV vectors
TW202102677A (zh) 經修飾腺病毒及含有其之醫藥
Branch TARGETING CANCER THERAPIES
HK40036361A (en) Oncolytic hsv vector
HK1225756B (en) Oncolytic hsv vector

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)